Loading clinical trials...
Loading clinical trials...
A Prospective, Single-arm, Single-center, Exploratory Study of the Safety and Efficacy of Adbelimumab Combined With Chemotherapy and Apatinib in Patients With Resectable Esophageal Squamous Cell Carcinoma
Conditions
Interventions
Adbelimumab, Albumin paclitaxel, Carboplatin, Apatinib
Esophagectomy
+1 more
Locations
1
China
2nd Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, China, China
Start Date
August 8, 2024
Primary Completion Date
December 1, 2026
Completion Date
December 1, 2031
Last Updated
December 2, 2025
NCT07463573
NCT06747585
NCT07437898
NCT04290806
NCT06764355
NCT07359417
Lead Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions